ID

31593

Beschreibung

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00736645

Link

https://clinicaltrials.gov/show/NCT00736645

Stichworte

Versionen (1)
  1. 10.09.18 10.09.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

10. September 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostate Cancer NCT00736645

Englisch

Eligibility Prostate Cancer NCT00736645

1 Formulare  
Criteria
Beschreibung

Criteria

histologically proven adenocarcinoma of the prostate
Beschreibung

Adenocarcinoma of prostate

Datentyp

boolean

Alias
UMLS CUI [1]
C0007112
diagnosed by sextant or greater biopsy
Beschreibung

Diagnosis Sextant biopsy | Diagnosis Biopsy Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0011900
UMLS CUI [1,2]
C3846092
UMLS CUI [2,1]
C0011900
UMLS CUI [2,2]
C0005558
UMLS CUI [2,3]
C1265611
clinical stage < t3 (stage i or ii) disease
Beschreibung

Disease TNM clinical staging

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3258246
prostate-specific antigen < 20.0 ng/ml
Beschreibung

Prostate specific antigen measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0201544
gleason score < 8
Beschreibung

Gleason score

Datentyp

boolean

Alias
UMLS CUI [1]
C3203027
scheduled to undergo prostatectomy or brachytherapy
Beschreibung

Prostatectomy Scheduled | Brachytherapy Scheduled

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0033573
UMLS CUI [1,2]
C0205539
UMLS CUI [2,1]
C0006098
UMLS CUI [2,2]
C0205539
patient characteristics:
Beschreibung

Client Characteristics

Datentyp

boolean

Alias
UMLS CUI [1]
C0815172
life expectancy > 5 years
Beschreibung

Life Expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
no other prior malignancy (excluding nonmelanoma skin cancer) in the past 5 years
Beschreibung

Exclusion | Cancer Other | Exception Skin carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2]
C1707251
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
willing and able to take finasteride, selenomethionine, and/or placebo for 3-5 weeks prior to prostatectomy/brachytherapy
Beschreibung

Finasteride | Selenomethionine | Placebo

Datentyp

boolean

Alias
UMLS CUI [1]
C0060389
UMLS CUI [2]
C0036584
UMLS CUI [3]
C1696465
prior concurrent therapy:
Beschreibung

Therapeutic procedure

Datentyp

boolean

Alias
UMLS CUI [1]
C0087111
more than 1 year since prior finasteride, dutasteride, sereona repens (saw palmetto), or any other 5-α reductase inhibitor
Beschreibung

Finasteride Previous | Dutasteride Previous | Serenoa repens extract Previous | Saw palmetto extract Previous | 5-alpha Reductase Inhibitors Previous

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0060389
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0754659
UMLS CUI [2,2]
C0205156
UMLS CUI [3,1]
C3491902
UMLS CUI [3,2]
C0205156
UMLS CUI [4,1]
C0771607
UMLS CUI [4,2]
C0205156
UMLS CUI [5,1]
C2936788
UMLS CUI [5,2]
C0205156
no prior hormonal therapy or radiotherapy
Beschreibung

Exclusion Criteria | Hormone Therapy | Therapeutic radiology procedure

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0279025
UMLS CUI [3]
C1522449
more than 30 days since prior and no concurrent participation in any other clinical trial involving a medical, surgical, nutritional, or life-style intervention (e.g., dietary modification or exercise)
Beschreibung

Exclusion Criteria | Study Subject Participation Status Involving Therapeutic intervention | Study Subject Participation Status Involving Surgical intervention | Study Subject Participation Status Involving Nutritional Intervention | Study Subject Participation Status Involving Life Style Intervention | Dietary Modification | Exercise

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C1314939
UMLS CUI [2,3]
C0087111
UMLS CUI [3,1]
C2348568
UMLS CUI [3,2]
C1314939
UMLS CUI [3,3]
C0549433
UMLS CUI [4,1]
C2348568
UMLS CUI [4,2]
C1314939
UMLS CUI [4,3]
C1882127
UMLS CUI [5,1]
C2348568
UMLS CUI [5,2]
C1314939
UMLS CUI [5,3]
C0023676
UMLS CUI [5,4]
C0184661
UMLS CUI [6]
C0086153
UMLS CUI [7]
C0015259
no concurrent selenium dietary supplement at doses > 200 mg/day, including multivitamin supplements
Beschreibung

Exclusion Criteria | Selenium supplement Dose U/day | Multivitamin Supplements

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0521939
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0456683
UMLS CUI [3,1]
C0301532
UMLS CUI [3,2]
C0242295
at least 30 days since > 200mg/day of prior selenium dietary supplement
Beschreibung

Selenium supplement Previous U/day

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0521939
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C0456683
no other concurrent hormonal therapy, including 5-α reductase inhibitors (e.g., finasteride or dutasteride); anti-androgens (e.g., bicalutamide, flutamide, or ketoconazole); or luteinizing hormone-releasing hormone agonists (e.g., leuprolide acetate, goserelin acetate, or abarelix)
Beschreibung

Exclusion Criteria | Hormone Therapy | 5-alpha Reductase Inhibitors | Finasteride | Dutasteride | Androgen Antagonists | bicalutamide | Flutamide | Ketoconazole | Luteinizing Hormone-releasing Hormone Agonist | Leuprolide Acetate | Goserelin Acetate | abarelix

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0279025
UMLS CUI [3]
C2936788
UMLS CUI [4]
C0060389
UMLS CUI [5]
C0754659
UMLS CUI [6]
C0002842
UMLS CUI [7]
C0285590
UMLS CUI [8]
C0016384
UMLS CUI [9]
C0022625
UMLS CUI [10]
C1518041
UMLS CUI [11]
C0700596
UMLS CUI [12]
C0700476
UMLS CUI [13]
C0965390
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Prostate Cancer NCT00736645

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Adenocarcinoma of prostate
Item
histologically proven adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Diagnosis Sextant biopsy | Diagnosis Biopsy Quantity
Item
diagnosed by sextant or greater biopsy
boolean
C0011900 (UMLS CUI [1,1])
C3846092 (UMLS CUI [1,2])
C0011900 (UMLS CUI [2,1])
C0005558 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Disease TNM clinical staging
Item
clinical stage < t3 (stage i or ii) disease
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Prostate specific antigen measurement
Item
prostate-specific antigen < 20.0 ng/ml
boolean
C0201544 (UMLS CUI [1])
Gleason score
Item
gleason score < 8
boolean
C3203027 (UMLS CUI [1])
Prostatectomy Scheduled | Brachytherapy Scheduled
Item
scheduled to undergo prostatectomy or brachytherapy
boolean
C0033573 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
C0006098 (UMLS CUI [2,1])
C0205539 (UMLS CUI [2,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Life Expectancy
Item
life expectancy > 5 years
boolean
C0023671 (UMLS CUI [1])
Exclusion | Cancer Other | Exception Skin carcinoma
Item
no other prior malignancy (excluding nonmelanoma skin cancer) in the past 5 years
boolean
C2828389 (UMLS CUI [1])
C1707251 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
Finasteride | Selenomethionine | Placebo
Item
willing and able to take finasteride, selenomethionine, and/or placebo for 3-5 weeks prior to prostatectomy/brachytherapy
boolean
C0060389 (UMLS CUI [1])
C0036584 (UMLS CUI [2])
C1696465 (UMLS CUI [3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Finasteride Previous | Dutasteride Previous | Serenoa repens extract Previous | Saw palmetto extract Previous | 5-alpha Reductase Inhibitors Previous
Item
more than 1 year since prior finasteride, dutasteride, sereona repens (saw palmetto), or any other 5-α reductase inhibitor
boolean
C0060389 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0754659 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C3491902 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C0771607 (UMLS CUI [4,1])
C0205156 (UMLS CUI [4,2])
C2936788 (UMLS CUI [5,1])
C0205156 (UMLS CUI [5,2])
Exclusion Criteria | Hormone Therapy | Therapeutic radiology procedure
Item
no prior hormonal therapy or radiotherapy
boolean
C0680251 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
Exclusion Criteria | Study Subject Participation Status Involving Therapeutic intervention | Study Subject Participation Status Involving Surgical intervention | Study Subject Participation Status Involving Nutritional Intervention | Study Subject Participation Status Involving Life Style Intervention | Dietary Modification | Exercise
Item
more than 30 days since prior and no concurrent participation in any other clinical trial involving a medical, surgical, nutritional, or life-style intervention (e.g., dietary modification or exercise)
boolean
C0680251 (UMLS CUI [1])
C2348568 (UMLS CUI [2,1])
C1314939 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C2348568 (UMLS CUI [3,1])
C1314939 (UMLS CUI [3,2])
C0549433 (UMLS CUI [3,3])
C2348568 (UMLS CUI [4,1])
C1314939 (UMLS CUI [4,2])
C1882127 (UMLS CUI [4,3])
C2348568 (UMLS CUI [5,1])
C1314939 (UMLS CUI [5,2])
C0023676 (UMLS CUI [5,3])
C0184661 (UMLS CUI [5,4])
C0086153 (UMLS CUI [6])
C0015259 (UMLS CUI [7])
Exclusion Criteria | Selenium supplement Dose U/day | Multivitamin Supplements
Item
no concurrent selenium dietary supplement at doses > 200 mg/day, including multivitamin supplements
boolean
C0680251 (UMLS CUI [1])
C0521939 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0301532 (UMLS CUI [3,1])
C0242295 (UMLS CUI [3,2])
Selenium supplement Previous U/day
Item
at least 30 days since > 200mg/day of prior selenium dietary supplement
boolean
C0521939 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Exclusion Criteria | Hormone Therapy | 5-alpha Reductase Inhibitors | Finasteride | Dutasteride | Androgen Antagonists | bicalutamide | Flutamide | Ketoconazole | Luteinizing Hormone-releasing Hormone Agonist | Leuprolide Acetate | Goserelin Acetate | abarelix
Item
no other concurrent hormonal therapy, including 5-α reductase inhibitors (e.g., finasteride or dutasteride); anti-androgens (e.g., bicalutamide, flutamide, or ketoconazole); or luteinizing hormone-releasing hormone agonists (e.g., leuprolide acetate, goserelin acetate, or abarelix)
boolean
C0680251 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C2936788 (UMLS CUI [3])
C0060389 (UMLS CUI [4])
C0754659 (UMLS CUI [5])
C0002842 (UMLS CUI [6])
C0285590 (UMLS CUI [7])
C0016384 (UMLS CUI [8])
C0022625 (UMLS CUI [9])
C1518041 (UMLS CUI [10])
C0700596 (UMLS CUI [11])
C0700476 (UMLS CUI [12])
C0965390 (UMLS CUI [13])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video